recent
outbreak
sever
acut
respiratori
syndrom
sar
provid
opportun
studi
antibodi
respons
infect
individu
caus
viru
sar
coronaviru
examin
serum
sampl
obtain
patient
sar
patient
nonsar
pneumonia
healthi
individu
use
western
blot
wb
enzymelink
immunoassay
elisa
immunofluoresc
assay
use
nativ
bacteri
produc
antigen
viru
found
highli
restrict
immunoglobulin
gdomin
antibodi
respons
patient
sar
direct
frequent
elisa
predominantli
nucleocapsid
almost
subject
without
sar
antinucleocapsid
antibodi
spike
protein
next
frequent
target
patient
elisa
respond
target
respons
identifi
use
wb
includ
antigen
kda
sever
nonstructur
protein
clone
antigen
culturederiv
nucleocapsid
appear
specif
degrad
peptidas
n
initi
attach
viral
e
protein
fuse
plasma
membran
host
cell
cascad
intracellular
event
follow
includ
interact
n
protein
interact
import
packag
progeni
virion
infect
patient
sar
develop
antibodi
viru
experi
seroconvers
within
day
howev
littl
els
known
antibodi
respons
patient
convent
antibodi
test
detect
antibodi
antigen
present
virusinfect
cell
use
immunofluoresc
assay
ifa
reveal
viral
antigen
target
immun
respons
know
viral
target
import
sever
reason
first
allow
develop
cellfre
antibodi
test
less
cumbersom
subject
ifa
use
mass
screen
time
epidem
second
enhanc
understand
immunopatholog
diseas
moreov
help
design
vaccin
humor
cellular
arm
adapt
immun
respons
presum
import
control
prepar
u
react
serum
sampl
patient
sar
show
highli
reactiv
antigensnucleocapsid
n
former
mw
molecular
weight
marker
kda
c
wb
result
patient
sar
patient
nonsar
pneumonia
p
show
strong
reactiv
antigen
lesser
reactiv
spike
protein
partial
reactiv
total
lack
reactiv
infect
cov
antibodi
function
block
adsorpt
entri
viru
target
cell
interf
viral
transcript
present
studi
identifi
viral
antigen
patient
sar
respond
patient
control
subject
diagnos
sar
accord
world
health
organ
criteria
basi
follow
symptom
acut
onset
fever
accompani
frequent
chill
rigor
dyspnea
headach
myalgia
hypoxemia
radiolog
evid
pneumonia
addit
patient
sar
antisar
cov
igg
antibodi
detect
use
ifa
show
seroconvers
increas
titer
assay
use
virusinfect
monkey
kidney
vero
cell
perform
routin
laboratori
serum
titer
consid
posit
patient
male
femal
age
rang
year
age
year
contact
mean
sd
patient
confirm
sar
within
day
onset
symptom
admit
princ
wale
hospit
hong
kong
sar
outbreak
start
earli
march
two
patient
die
requir
intens
care
eventu
recov
rest
mild
clinic
cours
method
detect
avail
earli
outbreak
sar
cov
cultur
patient
viral
rna
detect
use
reversetranscript
polymeras
chain
reaction
pcr
respiratori
stool
sampl
patient
serum
sampl
use
present
studi
obtain
day
day
mean
sd
onset
fever
control
subject
includ
inpati
male
femal
age
rang
year
mean
age
year
present
princ
wale
hospit
clinic
featur
atyp
pneumonia
treat
accordingli
hospit
emerg
sar
healthi
individu
blood
donor
student
institut
approv
human
anim
ethic
obtain
studi
institut
guidelin
follow
viral
cultur
crude
nativ
antigen
vero
cell
atcc
grown
dulbecco
modifi
eagl
medium
contain
fetal
calf
serum
co
humidifi
incub
sar
cov
strain
genbank
access
use
isol
patient
hospit
incub
h
ice
supernat
obtain
cell
lysat
centrifug
heat
min
inactiv
live
viru
present
store
use
control
cell
lysat
similarli
prepar
uninfect
vero
cell
recombin
viral
antigen
total
rna
extract
sar
covinfect
vero
cell
use
qiamp
viral
rna
kit
qiagen
reversetranscrib
random
hexam
appli
biosystem
cdna
obtain
use
gener
variou
gene
segment
follow
forward
f
primer
contain
site
underlin
revers
r
primer
contain
site
underlin
use
pcr
describ
elsewher
correspond
gene
segment
size
pcr
condit
use
min
cycl
min
min
min
min
geland
affinitypurifi
fragment
clone
bacteri
express
vector
amersham
bioscienc
fuse
bacteri
glutathion
stransferas
gst
gene
ligat
vector
transfect
escherichia
coli
recombin
antigen
recov
select
transform
induc
isopropylbdthiogalactopyranosid
brief
cell
pellet
resuspend
icecold
lysi
buffer
mmoll
trishcl
mmoll
nacl
triton
mmoll
pmsf
proteas
inhibitor
cocktail
ph
sigma
sonic
mm
recombin
antigen
recov
supernat
lysat
use
affin
chromatographi
use
glutathionecoupl
agaros
amersham
elut
mmoll
trishcl
buffer
ph
contain
mmoll
reducedform
glutathion
mmoll
nacl
triton
mmoll
ddt
elut
antigen
examin
sdspage
gel
stain
coomassi
blue
expect
size
good
puriti
observ
case
data
shown
sdspage
antigen
prepar
heat
min
load
buffer
moll
trishcl
ph
glycerol
sd
bromophenol
blue
electrophores
v
min
room
temperatur
rt
polyacrylamid
antigen
interest
ps
locat
unstain
gel
use
parallel
gel
stain
coomassi
blue
recov
elut
harvard
bioscienc
v
overnight
mmoll
tri
buffer
ph
contain
mmoll
glycin
methanol
sd
experi
whole
gel
electroblot
onto
polyvinyliden
fluorid
membran
biorad
use
protein
sequenc
protein
facil
iowa
state
univers
wb
latter
assay
membran
block
skim
milk
incub
h
rt
unknown
human
mous
serum
dilut
ml
pb
contain
skim
milk
wash
blot
incub
h
rt
peroxidaselabel
goat
antihuman
igg
antimous
ig
class
bd
bioscienc
later
chemiluminesc
substrat
ecl
amersham
assay
develop
exposur
hyperfilmb
max
amersham
inhibit
wb
unknown
serum
ml
preincub
inhibit
antigen
mgml
ml
pb
contain
skim
milk
overnight
elisa
nativ
viral
antigen
either
crude
purifi
ps
stock
dilut
recombin
antigen
rna
rsa
rsb
rsc
mgml
coat
onto
plate
dynex
bicarbon
buffer
ph
overnight
assay
perform
describ
elsewher
brief
ml
unknown
human
serum
dilut
pb
contain
bovin
serum
albumin
casein
ad
well
incub
min
rt
plate
wash
incub
min
rt
horseradish
peroxidaselabel
goat
antihuman
ig
igg
igm
iga
specif
bd
bioscienc
wash
substrat
tetramethylbenzidin
ad
reaction
allow
min
rt
result
read
nm
dynex
mrx
ii
reader
mous
immun
balbc
mice
micegroup
inject
intraperiton
affinitypurifi
alumprecipit
antigen
mgmous
complet
freund
adjuv
receiv
booster
inject
mg
antigen
incomplet
freund
adjuv
week
later
blood
obtain
retroorbit
plexu
day
administr
booster
inject
statist
relationship
rna
elisa
immunoassay
sampl
time
examin
use
regress
analysi
graphpad
prism
graphpad
softwar
first
examin
antibodi
respons
patient
sar
use
wb
figur
show
gelsepar
crude
extract
culturegrown
viru
sever
virusspecif
antigen
discern
compar
control
uninfect
extract
viral
extract
particularli
one
kda
molecular
weight
antigen
protein
label
respect
shown
immunoblot
serum
sampl
obtain
patient
sar
figur
rel
abund
vari
among
batch
extract
actual
doublet
consist
lowest
quantiti
wb
result
repres
patient
sar
patient
nonsar
pneumonia
shown
figur
result
base
igg
respons
igm
reaction
either
weak
absent
antigen
reactiv
antigen
found
patient
sar
absent
patient
nonsar
pneumonia
antigen
alway
appear
triplet
one
nonsar
serum
sampl
react
weakli
antigen
posit
lessreact
antigen
found
kda
seen
nonsar
serum
sampl
molecular
size
suggest
nucleocapsid
could
identifi
way
protein
sequenc
antigen
success
confirm
antigen
sdldr
protein
basi
wb
result
total
patient
sar
patient
nonsar
pneumonia
healthi
subject
patient
sar
produc
antibodi
antigen
produc
antibodi
protein
figur
addit
patient
sar
produc
antibodi
antigen
respect
data
shown
none
control
subject
produc
antibodi
antigen
although
serum
sampl
patient
nonsar
pneumonia
show
weak
reactiv
presum
antigen
see
sar
serum
sampl
posit
viral
antibodi
examin
use
ifa
use
infect
cell
although
low
titer
figur
none
serum
sampl
control
cohort
examin
posit
either
ifa
wb
use
bigger
studi
group
patient
sar
patient
nonsar
pneumonia
healthi
individu
examin
antibodi
respons
use
elisa
first
crude
viral
extract
use
antigen
patient
sar
posit
antibodi
compar
combin
control
subject
figur
patient
sar
neg
antibodi
low
ifa
titer
serum
sampl
reactiv
control
antigen
gst
data
shown
result
base
igg
respons
igm
respons
contrast
less
robust
less
frequent
among
patient
sar
figur
less
discriminatori
sar
nonsar
cohort
second
made
recombin
antigen
ntermin
half
n
protein
rna
use
igg
elisa
found
result
almost
ident
found
crude
viral
extract
sensit
specif
includ
neg
case
common
figur
igm
respons
similarli
low
infrequ
among
patient
sar
data
shown
investig
possibl
serum
sampl
neg
weakli
posit
elisa
ifa
posit
might
antibodi
direct
antigen
nucleocapsid
present
crude
extract
thu
examin
recombin
antigen
made
sever
nsp
viru
howev
although
subunit
found
nonantigen
show
weak
reactiv
serum
sampl
patient
sar
data
shown
nativ
antigen
purifi
use
elisa
detect
antibodi
respons
patient
sar
figur
slightli
detect
use
wb
howev
respons
weak
use
recombin
antigen
found
ctermin
end
rsc
protein
antigen
small
number
serum
sampl
patient
sar
reactiv
similar
result
serum
sampl
patient
nonsar
pneumonia
figur
purifi
nativ
antigen
togeth
gelsepar
crude
extract
use
elisa
result
obtain
similar
rna
elisa
particularli
respect
neg
posit
case
figur
suggest
might
antigen
relat
rna
investig
possibl
perform
wb
experi
use
rna
inhibitor
rna
inde
found
reduc
reactiv
also
figur
fact
inhibit
greatest
least
interest
appear
fourth
minor
n
fragment
molecular
weight
kda
figur
seen
serum
sampl
eg
figur
similar
result
obtain
purifi
antigen
use
inhibitor
wb
analysi
figur
contrast
antigen
rsc
use
inhibitor
reactiv
region
affect
ie
abolish
figur
prove
n
antigen
mous
serum
made
recombin
antigen
rna
rsa
rsc
rsb
avail
time
use
wb
crude
viral
extract
mice
immun
rna
produc
antibodi
react
specif
antigen
figur
figur
comparison
effici
variou
detect
assay
sever
acut
respiratori
syndrom
sar
individu
serum
sampl
group
patient
sar
patient
nonsar
pneumonia
healthi
individu
examin
use
immunofluoresc
assay
ifa
western
blot
wb
elisa
antigen
use
includ
nativ
spike
nativ
nucleocapsid
n
crude
antigen
crude
viral
extract
recombin
nucleocapsid
rna
gelpurifi
nativ
antigen
gelpurifi
nativ
spike
ps
recombin
spike
rsc
except
mark
igm
test
base
detect
igg
test
cutoff
posit
shown
shade
bar
elisa
base
sd
valu
combin
cohort
patient
nonsar
pneumonia
healthi
individu
wb
intens
mean
reaction
arbitrarili
score
eye
strongest
serum
sampl
examin
lack
antigen
serum
result
readabl
shown
dot
contrast
neither
antigen
produc
antibodi
crude
extract
figur
n
antigen
sar
cov
stand
import
diagnost
antigen
viru
major
patient
develop
sar
elisa
produc
antibodi
antigen
present
antibodi
also
abund
antibodi
made
viru
clear
n
antigen
immunogen
found
even
bacteri
produc
fragment
induc
good
product
antibodi
mice
n
antigen
also
found
highli
immunogen
elk
cov
infecti
bronchiti
viru
found
n
antigen
predomin
antigen
crude
viral
extract
shown
good
correl
rna
crude
antigen
elisa
figur
contrast
weak
correl
rna
elisa
ifa
perform
serum
sampl
figur
result
due
fact
use
singledilut
measur
elisa
rather
titrat
serum
figur
possibl
antigen
extract
cell
becom
degrad
extract
case
noteworthi
serum
sampl
patient
nonsar
pneumonia
react
presum
compon
wb
neg
rna
elisa
result
suggest
reactiv
epitop
locat
elsewher
n
antigen
nonvir
vero
antigen
expect
detect
antin
antigen
antibodi
patient
sar
use
rna
elisa
improv
increas
interv
time
sampl
obtain
onset
fever
figur
thu
neg
case
serum
obtain
within
day
onset
fever
hand
serum
sampl
obtain
period
found
posit
although
mean
half
earli
sar
case
late
day
case
could
detect
import
note
use
serum
sampl
ifa
select
note
regard
antin
antibodi
respons
patient
sar
predomin
igg
antibodi
igm
antibodi
even
earli
second
week
cours
diseas
result
impli
strong
helper
cell
involv
exagger
cell
respons
probabl
also
account
pneumoniaassoci
immunopatholog
seen
patient
sar
n
antigen
may
import
may
inde
potent
b
cell
potent
cell
immunogen
import
candid
vaccin
although
antibodi
nucleocapsid
nonneutr
whether
antibodi
protect
way
observ
mous
hepat
viru
rotaviru
need
address
formal
latter
phenomenon
may
due
abil
iga
antibodi
enter
infect
cell
igatranscytosi
pathway
therebi
interf
viral
transcript
found
evid
n
antigen
degrad
cell
cultur
viru
degrad
specif
sinc
major
n
antigen
found
everi
prepar
crude
extract
use
minor
antigen
also
sometim
seen
presum
fulllength
protein
other
fragment
lack
vari
length
ctermin
end
high
specif
seen
consid
degrad
artifact
antigenextract
procedur
rather
suspect
cleav
caspas
vero
cell
cell
undergo
apoptosi
similar
eleouet
et
al
observ
n
antigen
transmiss
gastroenter
cov
n
antigen
antigen
one
often
target
immun
respons
patient
sar
howev
elisa
patient
respond
respons
gener
weak
possibl
hand
respons
underestim
antigen
contain
crude
extract
use
wb
elisa
degrad
underrepres
recombin
antigen
use
elisa
produc
bacteria
lack
necessari
glycosyl
normal
associ
nativ
antigen
see
http
wwwcbsdtudk
antigen
viru
target
immun
respons
presum
minor
exampl
antigen
latter
could
recent
postul
mrna
methyltransferas
antigen
patient
respond
could
protein
e
protein
viru
latter
small
kda
assess
wb
gel
presum
import
protect
